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The glutamate transporter gene, EAAT2/GLT-1, is induced
by epidermal growth factor (EGF) and downregulated by
tumor necrosis factor a (TNFa). While TNFa is generally
recognized as a positive regulator of NF-jB-dependent
gene expression, its ability to control transcriptional re-
pression is not well characterized. Additionally, the reg-
ulation of NF-jB by EGF is poorly understood. Herein, we
demonstrate that both TNFa-mediated repression and EGF-
mediated activation of EAAT2 expression require NF-jB.
We show that EGF activates NF-jB independently of sig-
naling to IjB. Furthermore, TNFa can abrogate IKKb- and
p65-mediated activation of EAAT2. Our results suggest
that NF-jB can intrinsically activate EAAT2 and that
TNFa mediates repression through a distinct pathway also
requiring NF-jB. Consistently, we find that N-myc is
recruited to the EAAT2 promoter with TNFa and that
N-myc-binding sites are required for TNFa-mediated re-
pression. Moreover, N-myc overexpression inhibits both
basal and p65-induced activation of EAAT2. Our data
highlight the remarkable specificity of NF-jB activity to
regulate gene expression in response to diverse cellular
signals and have implications for glutamate homeostasis
and neurodegenerative disease.
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Introduction
The excitatory amino-acid transporter, EAAT2/GLT-1, is re-
sponsible for the majority of clearance of the neurotransmit-
ter glutamate from neuronal synapses in the central nervous
system (CNS) (Tanaka et al, 1997). Impaired glutamate
uptake by glial cells can result in cell death from excessive
levels of glutamate and overstimulation of glutamate recep-
tors (Choi, 1988). Indeed, glutamate toxicity is implicated in
a wide variety of neurodegenerative disorders, including
Alzheimer’s disease, amyotrophic lateral sclerosis and multi-
ple sclerosis (Doble, 1999). The importance of regulating
glutamate transport is underscored by the observation that
mice lacking EAAT2 develop progressive neurodegeneration
and epilepsy as a result of aberrant glutamate homeostasis
(Rothstein et al, 1996; Tanaka et al, 1997). Therefore, it is
extremely important to understand the regulation of EAAT2
expression in glial cells. Interestingly, EAAT2 is positively
regulated by epidermal growth factor (EGF) and negatively
regulated by the proinflammatory cytokine, tumor necrosis
factor a (TNFa) (Zelenaia et al, 2000; Schluter et al, 2002;
Su et al, 2003). However, the requirements for growth factor-
and cytokine-mediated regulation of EAAT2 expression have
not been clearly elucidated.
TNFa activates the NF-kB family of transcription factors,
which are ubiquitously expressed and are pivotal in control-
ling diverse cellular processes, including immune responses,
cell proliferation and differentiation (Israel, 2000; Baldwin,
2001; Silverman and Maniatis, 2001; Ghosh and Karin, 2002;
Li and Verma, 2002). Increasingly, it has become evident that
NF-kB also plays important roles in the CNS (O’Neill and
Kaltschmidt, 1997). In most cells, the predominant induced
NF-kB complex is a p65/RelA and p50 heterodimer, which is
generally a positive regulator of gene-specific transcription.
Activation of NF-kB typically involves regulating the stability
of the inhibitory protein, IkB. Signal-induced phosphoryla-
tion, ubiquitination and degradation of IkB induce NF-kB
nuclear accumulation and subsequent target-specific DNA
binding. Phosphorylation of IkB is carried out by the IkB
kinase (IKK) complex, which is comprised of IKKa, b and g
subunits (Israel, 2000; Ghosh and Karin, 2002; Yamamoto
and Gaynor, 2004). Notably, IKKb is the primary kinase
responsible for cytokine-induced IkB phosphorylation and
NF-kB activation (Ghosh and Karin, 2002).
The regulation of NF-kB activity by growth factors such as
EGF is less well understood. For example, EGF has been
reported to stabilize IkB and block NF-kB activation (Mehta
and Besner, 2003; Banan et al, 2004a, b). However, in carci-
noma cells that overexpress EGF receptor family members,
EGF has been shown to induce IkBa degradation and NF-kB
DNA binding (Sun and Carpenter, 1998; Biswas et al, 2000).
Additionally, NF-kB-inducing kinase (NIK) has been reported
to be complexed with the EGF receptor, which potentiates
EGF activation of NF-kB (Chen et al, 2003). Consistent with
EGF-controlled activation of NF-kB, Anest et al (2004) have
recently reported positive regulation of the immediate-early
gene c-fos by NF-kB through a mechanism involving consti-
tutive association of p65 with the promoter. Clearly, further
studies are necessary to understand the regulation of EGF-
responsive genes by NF-kB.
The opposing regulation of EAAT2 expression by cytokines
and growth factors provides a unique opportunity to study
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how different physiological or pathological signals elicit
distinct transcriptional responses from a single promoter. In
this work, we establish that both positive and negative
regulation of EAAT2 gene expression are controlled by
NF-kB. We show that EGF induces NF-kB recruitment to the
EAAT2 promoter in a manner that does not involve IkB
degradation or enhanced p65/RelA nuclear accumulation.
Furthermore, our data reveal that NF-kB is an intrinsic
positive regulator of EAAT2 gene expression and that TNFa-
mediated repression involves another transcription factor,
N-myc. These experiments have important implications for
understanding differential gene expression as well as the
altered glutamate homeostasis associated with different
CNS disorders.
Results
EGF and TNFa differentially regulate EAAT2 expression
Previous reports have demonstrated that diverse signals can
positively or negatively regulate the expression of EAAT2 in
astrocytes and we sought to determine whether this dual
regulation occurred in human H4 astroglioma cells. Using
quantitative real-time RT–PCR analysis in wild-type H4 cells,
we observed induction of EAAT2 mRNA in response to
treatment with EGF (Figure 1A). In contrast, in response to
TNFa treatment and consistent with previous reports
(Su et al, 2003), EAAT2 mRNA expression was decreased.
Given the strong role of NF-kB in TNFa-induced gene
expression and the less well-established role of this transcrip-
tion factor in EGF-induced gene expression, we analyzed the
EAAT2 proximal promoter sequence for potential NF-kB-
dependent regulatory elements. We identified six putative
NF-kB consensus binding sites, including two sites (þ 133
and þ 265) in the region corresponding to the 50 untranslated
region (50UTR) (Figure 1B). The 583 and 272 sites were
previously reported and a reporter construct containing these
NF-kB sites in the EAAT2 promoter was shown to remain
responsive to both EGF- and TNFa-mediated regulation
(Su et al, 2003). Results from our initial studies found that
changes in EAAT2 mRNA levels were not due to alterations in
NF-kB p65 or p50 protein levels resulting from EGF or TNFa
treatments (data not shown), raising the potential that altera-
tion of NF-kB transcriptional activity is associated with the
differential control of EAAT2 gene expression by growth
factors and cytokines.
NF-jB is recruited to the EAAT2 promoter in response
to TNFa and EGF
To address the potential role of NF-kB in regulating EAAT2
gene expression, we asked whether TNFa and EGF induce
NF-kB DNA binding to the consensus sites in the EAAT2
promoter. Electrophoretic mobility shift assays (EMSAs) were
performed with nuclear extracts from H4 cells treated with
TNFa or EGF. TNFa strongly induced DNA/protein complex
formation at the 583 position, which consists of the con-
sensus sequence 50-GGGGCATCCC-30 (Figure 2A). The
binding of complex 1 was rapidly induced after 15 min
of treatment and persisted for at least 4 h. Complex 2 was
induced with slightly slower kinetics. We observed that EGF
treatment also induced binding to this element, albeit weakly
as compared to that of TNFa. EGF induction of complex 1
occurred at 1 h and complex 2 was also more weakly induced
(Figure 2A). Experiments were also performed with a probe
in which the 583 consensus site was mutated in order to
determine whether the induced binding was specific for NF-
kB. Indeed, both TNFa- and EGF-induced NF-kB complexes
did not form with the mutated probe (Figure 2B). The EGF-
induced increase in NF-kB DNA binding to the 583 site was
further investigated using a DNA affinity purification assay
(DAPA) where nuclear proteins were allowed to bind to an
immobilized, biotinylated oligo containing the 583 se-
quence (see Materials and methods). Bound proteins were
eluted and subsequently analyzed by Western blot with a
p65-specific antibody. We found that NF-kB p65 DNA binding
to the 583 site of the EAAT2 promoter was strongly in-
creased in response to TNFa and weakly increased in re-
sponse to EGF (Figure 2C). Results from these experiments
clearly confirmed our EMSA results and also identified the
NF-kB p65 subunit as part of both TNFa- and EGF-induced
DNA-binding complexes.
To further characterize the proteins in the EMSA com-
plexes, we performed supershift assays with antibodies to
specific NF-kB family members. In TNFa-treated cells, com-
plex 1 was completely supershifted with a-p65 and a-p50
antibodies and complex 2 was partially supershifted with
a-p50 (Figure 2D). In EGF-treated cells, although weak super-
shifted bands were formed, we observed complete loss of






















































Figure 1 EAAT2 expression is differentially regulated by TNFa and
EGF. (A) Quantitative real-time RT–PCR analysis of EAAT2 mRNA
levels in H4 glioma cells treated with EGF or TNFa. PCR reactions
were performed in triplicate and EAAT2 mRNA levels were normal-
ized to b-actin as an endogenous control. (B) NF-kB and N-myc
consensus sites in the EAAT2 promoter. The relative positions and
sequences of putative NF-kB and N-myc DNA-binding sites are
indicated. Arrows indicate the position of primers used for ChIPs
(Figures 3 and 7).
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complex 1 binding by incubating nuclear extracts with a-p65
or a-p50, indicating that these antibodies did not generate a
clear supershift but nevertheless, specifically interfered with
complex 1 formation. Results from these experiments demon-
strated that the TNFa- and EGF-induced NF-kB complex 1
primarily consists of the p65–p50 heterodimer (Figure 2D).
The TNFa-induced complex 2 contains p50 as well as
the p52 subunit, whereas c-Rel and RelB are absent (see
Supplementary data).
Next, we examined NF-kB binding to one of the putative
consensus NF-kB sites in the region of the EAAT2 gene
corresponding to the 50UTR. Interestingly, we observed a
different pattern of binding to the þ 265 site, which consists
of the sequence 50-GGGGCGTTCCC-30. Results from EMSAs
showed that EGF strongly induced NF-kB binding in a
manner comparable to that of TNFa (Figure 2E).
Additionally, EGF induced binding at 30 min that was dimin-
ished by 4 h post-treatment. In contrast, TNFa rapidly in-
duced NF-kB binding 15 min after the addition of EGF and
this binding persisted for up to 4 h, which is a pattern similar
to that seen with TNFa at the 583 site (Figure 2A). We
observed three specific complexes that bind to the þ 265 site,
EκΒ (−583) wild type : GGGGCATCCC
EκΒ (−583) mutant: GGTTCATCAA
Complex 1
Complex 2
TNFα (h) EGF (h)
0 0.25 0.5 1 2 4 0 0.25 0.5 1 2 4
0 0.25 0.5 1 2 4 0 0.25 0.5 1 2 4
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Figure 2 TNFa and EGF induce NF-kB DNA binding at the EAAT2 promoter. (A) EMSAs were performed with nuclear extracts from H4 cells
treated with TNFa or EGF over a 4 h time course using a probe corresponding to the wild-type 583 site (EkB (583)). A darker gel exposure is
shown in the EGF panel to better visualize weak induction of DNA binding. (B) NF-kB binding using the same extracts from (A) was compared
to a mutant EkB (583) site. Mutated sequences are underlined. (C) DAPAs were performed by incubating H4 nuclear extracts with an
immobilized, biotinylated EkB (583) double-stranded oligo. Bound protein complexes were washed, eluted with 1 sample buffer and
subjected to PAGE and Western blot analysis with a p65-specific antibody. (D) EMSAs were performed using nuclear extracts from cells treated
with TNFa (0.5 h) or EGF (4 h) in the presence or absence of p65 or p50 antibodies. Supershifted complexes are indicated with asterisks (*p65,
**p50). (E) EMSA was performed with a probe corresponding to the þ 265 site in the EAAT2 50UTR using H4 nuclear extracts treated with
TNFa or EGF over a 2 h time course. (F) EMSA was performed using a mutant þ 265 probe. Mutated sequences are underlined.
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and mutation of this site eliminated complex formation
(Figure 2F). Supershift analyses indicated that the inducible
complex 2 is a heterodimer of the p65 and p50
NF-kB subunits (see Supplementary data). We are currently
investigating the nature of the additional bands that form
at the þ 265 site. Additionally, we observed binding to other
NF-kB sites in the EAAT2 promoter, including 334 as well
the three sites at 272, 251 and þ 133 (see Supplementary
data).
To examine the kinetics of in vivo recruitment of NF-kB
proteins to the EAAT2 promoter in untreated and EGF- or
TNFa-treated H4 cells, we performed chromatin immunopre-
cipitation (ChIP) assays using a p65-specific antibody (Figure
3A and B). The kinetics of detectable p65 recruitment to the
EAAT2 promoter is greater with TNFa than EGF treatment
over the course of 4 h. Moreover, the overall levels of p65
recruitment are approximately three times greater with TNFa
compared with that of EGF. Although ChIP analysis does not
itself measure affinity or the extent of promoter occupancy,
the kinetics of p65 promoter recruitment by this approach is
consistent with results from the EMSAs and real-time PCR
analysis of EAAT2 expression. Overall, these data indicate
that TNFa and EGF induce NF-kB recruitment to the EAAT2
promoter in vivo and that the subunit composition of NF-kB
complexes is similar for both inducers.
Positive and negative regulation of EAAT2 gene
expression requires NF-jB
Thus far, our data demonstrate in vitro and in vivo that EGF
and TNFa induce the formation of NF-kB DNA-binding com-
plexes that are correlated with either transcriptional activa-
tion or repression. To determine whether regulation of EAAT2
expression required NF-kB, we tested the activity of an
EAAT2 promoter-driven luciferase reporter and compared
this to EAAT2 reporters that had mutations in NF-kB con-
sensus sites (Figure 4A). Mutation of the 583 site signifi-
cantly impaired the constitutive activation of EAAT2,











































Figure 3 NF-kB p65 is present at the EAAT2 promoter in vivo in
response to EGF and TNF. (A) H4 cells were treated with TNFa
(20 ng/ml) or EGF (50 ng/ml) for the indicated time points. ChIP
assays were performed using a p65-specific antibody. IgG precipita-
tions are shown as a negative control. Prior to immunoprecipita-
tion, a portion of samples was reserved for input controls.
Immunoprecipitated chromatin was prepared and subjected to
quantitative real-time PCR analysis using primers that amplify the
583 region (see Figure 1B and Materials and methods). Reactions
were performed in triplicate and values are represented as a
percentage of input DNA. (B) DNA from real-time PCR analysis






























































Figure 4 NF-kB is required for regulation of EAAT2 expression. (A)
Luciferase reporter assays were performed in H4 cells with wild-
type and mutant EAAT2 promoter constructs that had mutations
in three NF-kB consensus sites (see Materials and methods).
Treatments were performed with 20 ng/ml TNFa or 50 ng/ml EGF.
Transfections were performed in triplicate. Normalized RLUs (re-
lative luciferase units) represent luciferase activity normalized to a
Renilla reporter. (B) Wild-type and IkBa-SR-expressing H4 cells
were treated with TNFa or EGF for the indicated time points.
Total RNA was isolated, reverse-transcribed with MMLV-RT and
quantitative real-time PCR analysis of EAAT2 cDNA was subse-
quently performed. EAAT2 mRNA levels were normalized to b-actin
mRNA as an internal control.
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levels of gene expression. Indeed, the activity of a triple
mutant reporter (583, 272 and 251 sites) was completely
abolished. Interestingly, TNFa-mediated repression of repor-
ter activity was only partially abrogated with the 583
mutant reporter, whereas EGF-mediated activation was com-
pletely lost. The fact that TNFa-mediated repression is not
completely abolished with the 583 mutant likely reflects the
contribution of additional NF-kB sites that were not mutated.
When we examined the activity of an EAAT2 reporter in
which the NF-kB sites in the 50UTR (þ 133/þ 265) were
mutated, we again observed lower basal activity. However,
in this context, we observed complete loss of TNFa-mediated
repression, whereas EGF was still able to activate (Figure 4A).
These results suggest that distinct NF-kB sites may contribute
preferentially to activation or repression of EAAT2. Next, we
monitored EAAT2 mRNA levels in H4 astroglial cells expres-
sing either vector or IkBa super-repressor (SR), a nondegrad-
able, dominant-negative inhibitor of all NF-kB complexes.
Stable expression of IkBa-SR resulted in loss of NF-kB DNA-
binding activity as assayed by EMSAs (data not shown). H4
cells stably expressing IkBa-SR were no longer sensitive to
TNF-mediated inhibition of EAAT2 expression (Figure 4B) as
compared with cells expressing vector alone. Additionally,
induction of EAAT2 gene expression by EGF was also abro-
gated in H4 IkBa-SR cells. These results definitively show that
NF-kB activity is required for both TNFa-mediated inhibition
and EGF-mediated induction of EAAT2 expression in glial
cells.
TNFa and EGF use different signaling pathways
to regulate NF-jB
Given the clear quantitative and kinetic differences in the
ability of EGF and TNFa to elicit the formation of NF-kB DNA-
binding complexes at the EAAT2 promoter, we set out to
address whether these signals utilized the same pathways to
regulate NF-kB activity. We asked whether both EGF and
TNFa employed the classical mechanism of signal-induced
IkBa phosphorylation and degradation to trigger NF-kB nu-
clear localization. In H4 cells treated with TNF, the typical
kinetics of IkBa phosphorylation and degradation at
15–30 min were observed, which is consistent with induction
of DNA binding at that time point (Figure 5A). However,
treatment with EGF altered neither the phosphorylation nor
the stability of IkBa. Similar results were also observed with
IkBb and IkBe (Figure 5B). In order to confirm activation of
the EGF signaling pathway, we assessed whether down-
stream targets of that pathway were activated with treatment.
Indeed, we observe induction of MEK1/2 phosphorylation
after EGF treatment (Figure 5C). To determine whether EGF-
induced stabilization of IkB affected NF-kB levels in the
nucleus, we performed Western blot analysis of nuclear
extracts from H4 cells. Results from these experiments
showed that TNFa treatment results in greatly increased
nuclear p65 levels, whereas EGF did not significantly alter
the pre-existing, constitutive levels of nuclear p65
(Figure 5D). Together, these data suggest that TNFa acts
through the classical IkB degradation pathway to induce
NF-kB DNA binding and transcriptional repression, whereas
EGF regulates the activity of constitutively nuclear NF-kB
complexes independently of IkB to regulate positively EAAT2
expression.
TNFa-mediated repression overcomes intrinsic
activation of EAAT2 by NF-jB
We next asked whether the activating or repressive signal
would be dominant with cotreatment of H4 cells with
EGF and TNFa. Results from transient transfection assays
with the wild-type EAAT2-luciferase reporter show that
the repressive signal by TNFa prevents EGF-mediated activa-
tion of EAAT2. We sought to determine whether a signal
that elicits NF-kB activation alone would activate or
repress EAAT2 gene expression. Thus, we tested whether
overexpression of p65 or IKKb, which is essential for
TNFa-mediated activation of NF-kB, would positively or
negatively regulate EAAT2. Our results demonstrated that
p65 and IKKb expression dramatically increased wild-type
EAAT2 reporter activation (Figure 6A), suggesting that NF-kB
has an inherent ability to activate EAAT2. Interestingly,
TNFa treatment resulted in repression of both p65- and
IKKb-mediated EAAT2 activation. Mutation of the 583,
272 and 251 NF-kB sites resulted in a significant decrease
in basal EAAT2 expression and loss of the ability of IKKb
to induce gene expression (Figure 6B). Additionally, we
find that TNFa activates a reporter containing NF-kB
0  0.25 0.5 1 2 4 24 48 0  0.25 0.5 1 2 4 24 48
TNFα (h) EGF (h)
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Figure 5 EGF and TNFa signal to NF-kB via different signaling
pathways. Western blot analysis was performed with protein ex-
tracts from H4 cells that were treated with either TNF or EGF for the
indicated time points. Cytoplasmic fractions were used unless
otherwise indicated. Blots were reprobed with b-tubulin to demon-
strate equal loading of protein. (A) Total and phosphorylated IkBa
proteins. (B) IkBb and IkBe proteins. (C) Phosphorylated MEK1/2 in
whole cell lysates. (D) p65 protein levels in nuclear extracts from
cells treated with TNF or EGF.
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consensus sites from the MHC class I promoter, demonstrat-
ing that the repressive effects of TNFa are promoter specific
(Figure 6C). Based on these data, we suggest that TNFa
functions at two distinct levels to regulate NF-kB activity
and repress EAAT2 gene expression: (i) inducing NF-kB DNA
binding through IkB signaling and (ii) regulating different
signaling pathways and/or transcriptional regulators that
ultimately convert NF-kB to a transcriptional repressor (see
Figure 9).
A role for N-myc in TNFa-mediated repression of EAAT2
To address the mechanism by which TNFa induces repres-
sion, we investigated whether other regulatory factors
were involved. The EAAT2 promoter contains consensus
binding sites for several transcription factors, including
N-myc (see Figure 1B), a basic helix–loop–helix transcription
factor that is necessary for neurogenesis (Knoepfler et al,
2002) and is frequently amplified in neuroblastoma (Schwab,
1993). Using ChIP assays, we found that N-myc recruitment
to the EAAT2 promoter is significantly increased with
TNFa treatment as compared with EGF treatment (Figure
7A and B). Furthermore, using DNA purification assays,
we observed increased TNFa-induced N-myc DNA binding
to a probe spanning the 534 to 505 region of the EAAT2
promoter, which contains a putative CACGCG N-myc
site (Figure 7C). These data suggest that N-myc may be
involved in TNFa-mediated repression of EAAT2. To test
this possibility, we constructed an EAAT2-luciferase reporter
that had both N-myc consensus sites mutated and tested
its activity in transient transfection assays (see Materials
and methods). We observed that TNFa was unable to repress
the activity of the N-myc mutant reporter, while EGF
remained able to activate (Figure 8A). Next, we examined
whether overexpression of N-myc would affect the
basal activity of the EAAT2 promoter or the ability of
NF-kB to activate EAAT2. Indeed, in luciferase reporter
assays, we observed that N-myc repressed both basal
and p65-induced activation of the wild-type EAAT2
reporter in a dose-response manner (Figure 8B).
Importantly, the loss of NF-kB activation was not due
to decreased p65 or p50 protein levels by N-myc
(Figure 8B). Together, these data indicate that the preferen-
tial, early recruitment of N-myc to the EAAT2 promoter


































































Figure 6 TNFa-mediated repression overcomes activation of
EAAT2 by NF-kB. (A) The effect of TNFa on EGF-, IKKb- or p65-
mediated activation of the wild-type EAAT2 reporter was tested.
Normalized RLUs represent luciferase units normalized to Renilla
control reporter activity. (B) The ability of IKKb to regulate the triple
mutant EAAT2 reporter was tested and compared to that of wild
type. (C) TNFa-mediated repression is specific to the EAAT2 pro-
moter. The activity of a 3x-kB-luciferase promoter containing con-
sensus NF-kB sites from the MHC class I promoter was tested in the































Figure 7 N-myc is recruited to the EAAT2 promoter in vivo. Using
an N-myc antibody, ChIP assays were performed in H4 cells at
various time points in the presence or absence of TNFa or EGF.
Immunoprecipitated DNA was analyzed by (A) quantitative real-
time PCR and (B) agarose gel electrophoresis. (C) DAPAs were
performed by incubating H4 nuclear extracts with an immobilized,
biotinylated double-stranded oligo that contains an N-myc consen-
sus site (see Materials and methods). Bound protein complexes
were washed, eluted with 1 sample buffer and subjected to PAGE
and Western blot analysis with an N-myc-specific antibody.
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Discussion
Here we investigate the regulation of EAAT2/GLT-1 expres-
sion by growth factors and cytokines. We show that EAAT2
gene expression is negatively regulated by TNFa and posi-
tively regulated by EGF in H4 astroglioma cells. Previous
work suggesting that regulation of EAAT2 expression was
mediated by NF-kB was based on inhibiting NF-kB activity
using antioxidants, such as PDTC (Schreck et al, 1992; Sato
et al, 1996; Zelenaia et al, 2000; Su et al, 2003). However, it
has recently been demonstrated that these antioxidants have
pleiotropic effects and do not function as specific NF-kB
inhibitors (Hayakawa et al, 2003). Therefore, it was impor-
tant to determine the precise role of NF-kB in regulating
EAAT2 in response to growth factor and cytokine signals.
Here, we demonstrate that NF-kB is recruited to the EAAT2
promoter in vitro and in vivo in response to both EGF and
TNFa and that both of these signals induce the predominant
p65–p50 heterodimer (Figures 2 and 3). Our results from
experiments using IkBa-SR to prevent NF-kB activity defini-
tively establish that NF-kB is important for basal activation of
EAAT2 expression, and that both the positive regulation of
EAAT2 expression by EGF and negative regulation by TNFa
are dependent on NF-kB. The ability of IkBa-SR to abrogate
NF-kB-dependent transcriptional responses reflects the abil-
ity of this dominant-negative inhibitor to bind and sequester
all NF-kB complexes, regardless of whether they are normally
regulated in an IkBa-dependent manner. Interestingly, we
were unable to recapitulate fully EGF-mediated activation of
EAAT2 in fibroblast cells (data not shown), suggesting that
the opposing regulation of EAAT2 by TNFa and EGF may be
cell type specific. Overall, our results highlight the ability of
NF-kB to integrate diverse physiological or pathological
signals to specify either transcriptional activation or repres-
sion.
The presence of NF-kB consensus sites in the region
corresponding to the 50UTR of EAAT2 evokes the interesting
possibility of alternative mechanisms regarding both positive
and negative control of gene expression. Others have re-
ported a transcriptional regulatory role for the region be-
tween the transcription and translation start sites of several
genes, including HIV-1, HIV-2, adenovirus, human b-globin
and aggregan (Mansour et al, 1986; Jones et al, 1988; Amrolia
et al, 1995; Valhmu et al, 1998). Additionally, NF-kB binding
in the 50 intragenic regions of genes was recently reported
(Martone et al, 2003). Our finding that both TNFa and EGF
elicit strong NF-kB DNA binding at the þ 265 site suggests
that it is a functional regulatory element, which may
contribute to regulating gene expression in conjunction
with NF-kB sites present in the promoter (Figure 2).
Indeed, our results suggest that the distinct NF-kB sites in
the promoter proximal and 50UTR regions may differentially
contribute to gene activation or repression (Figure 4).
Although the mechanism of regulation by the NF-kB sites
in the EAAT2 50UTR has yet to be elucidated, it is possible
that TNFa-mediated NF-kB DNA binding in this region may
serve to hinder RNA polymerase (PolII) processivity and
elongation, thereby contributing to transcriptional repres-
sion.
Interestingly, we found that TNFa and EGF utilize distinct
signaling pathways to regulate NF-kB activity (Figure 5).
TNFa induces the classical IkB degradation pathway to
trigger NF-kB nuclear translocation and DNA binding to
repress EAAT2 expression. In contrast, EGF activates EAAT2
expression independently of IkB degradation and NF-kB
nuclear translocation. Therefore, our data suggest that EGF
induces the recruitment of pre-existing, constitutively nuclear
NF-kB complexes to the EAAT2 promoter. Generally, the
complex spatial and temporal regulation of gene expression
in higher eukaryotes is achieved through combinatorial reg-
ulation of transcription factors. Likewise, EGF may regulate
the activity of other regulators that cooperate with NF-kB to
activate expression of EAAT2 thereby allowing cells to finely
control gene transcription and integrate multiple signal trans-
duction pathways (Figure 9). The identity of EGF-induced
regulators is currently under investigation.
Although the mechanisms of NF-kB activation by TNFa are
well established, TNFa-mediated repression is poorly under-
stood. Transcriptional repression by NF-kB proteins is prob-
ably best exemplified by Dorsal, a Drosophila Rel family
member that can either activate or repress gene expression
through the recruitment of coactivators, such as CBP, or
corepressors such as Groucho (Belvin and Anderson, 1996).
Examples of NF-kB-mediated repression in mammals include
TNFa-mediated downregulation of collagen gene expression,
which involves activation of the Jun-N-terminal kinase (JNK)
and c-Jun transcription factor (Verrecchia et al, 2002).
Additionally, NF-kB has been reported to repress transcrip-
tion by inhibiting the transactivating function of other reg-
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Figure 8 N-myc-binding sites in the EAAT2 promoter are required
for N-myc- and TNFa-mediated repression. (A) Wild-type or N-myc
mutant reporters were transfected into H4 cells. Untreated and
TNFa- and EGF-treated cells were assayed for luciferase activity.
(B) The wild-type EAAT2-luciferase reporter in the absence or
presence of p65 was cotransfected H4 cells with increasing amounts
of N-myc. Western blot analysis with p65- or p50-specific antibodies
was performed on whole cell lysates from transfected cells.
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shown that other inducers, such as chemotherapeutic
agents, can elicit NF-kB transcriptional repression in a man-
ner that is dominant to TNFa-induced activation (Campbell
et al, 2004). Our results demonstrating the ability of TNFa
to overcome p65- and IKKb-mediated activation of EAAT2
expression suggest the acquisition of a repressive complex
through a distinct signaling pathway to block intrinsic
NF-kB-mediated gene activation. Indeed, the preferential
recruitment of N-myc to the EAAT2 promoter by TNFa
and the ability of N-myc to repress NF-kB-mediated activa-
tion of EAAT2 suggest a mechanism by which TNFa
may overcome intrinsic NF-kB-mediated activation.
Notably, N-myc does not significantly affect the expression
of NF-kB (Figure 8B). Therefore, in contrast to an earlier
report that describes N-myc-mediated repression of MHC
class I gene expression through downregulation of p50 (van
‘t Veer et al, 1993), our data suggest that N-myc blocks NF-kB
transcriptional activity at the EAAT2 promoter. Preliminary
immunoprecipitation experiments in transiently transfected
cells overexpressing N-myc indicate that repression occurs
through protein–protein interaction (data not shown). Given
that N-myc recruitment is weakly induced with EGF at later
time points in a manner similar to NF-kB, we cannot rule out
the possibility that N-myc plays a role in activation of EAAT2.
Alternatively, delayed recruitment of N-myc with EGF could
be involved in turning off gene expression at later time
points. Experiments addressing these possibilities are cur-
rently underway.
N-myc is a transcription factor that is critical for develop-
ment as N-myc null mice are embryonic lethal (Sawai
et al, 1991; Stanton et al, 1992), and conditionally deleting
N-myc in neuronal progenitor cells prevents proper nervous
system development (Knoepfler et al, 2002). However,
the function of this regulator in glial cells is not
known. Moreover, very few N-myc target genes have been
identified to date. Our data suggest that N-myc may
play a role in regulating EAAT2 expression and glutamate
uptake (Figures 7 and 8). Interestingly, increased N-myc
expression is observed in reactive astrocytes of brains of
patients with Alzheimer’s, Parkinson’s and Huntington’s
disease (Ferrer and Blanco, 2000), suggesting that aberrant
N-myc activity in glial cells may contribute to neurodegen-
erative pathologies.
Finally, the ability of NF-kB to regulate EAAT2 expression
has important implications for the regulation of glutamate
homeostasis in the CNS. To prevent the overstimulation
of neuronal glutamate receptors that can trigger excitotoxic
mechanisms and cell death, extracellular concentrations
of excitatory amino acids are tightly controlled by transport
systems on both neurons and glial cells (Danbolt,
2001). EAAT2 is critical for rapid clearance of synaptically
released glutamate for proper neurotransmission (Rothstein
et al, 1996, 2004). Accumulation of excessive glutamate
levels in neuronal synapses can lead to excitotoxic neuronal
death, which has been implicated in the pathogenesis
of numerous neurodegenerative diseases, as well as
CNS injury resulting from stroke and ischemia (Doble,
1999). Notably, these conditions have been associated
with increased NF-kB activity (Mattson and Camandola,
2001), and reduced EAAT2 expression is observed
after brain injury and in patients with Alzheimer’s disease,
Huntington’s disease, amyotrophic lateral sclerosis and
multiple sclerosis (Trotti, 2002; Maragakis et al,
2004). Interestingly, EAAT2 may also have a role in develop-
ment, as work in Drosophila demonstrates that this transpor-
ter is involved in terminal glial cell differentiation (Soustelle
et al, 2002). Moreover, reduced glial cell populations are
observed in mice lacking the EGF receptor (Kornblum et al,
1998), suggesting that EGF signaling is also important for
glial cell differentiation. Based on our work in this study, we
propose that positive regulation of EAAT2 by NF-kB in
response to EGF may promote glial cell differentiation and
uptake of synaptic glutamate by glial cells, whereas TNFa-
mediated inhibition of EAAT2 by NF-kB may contribute to

















Figure 9 A model for the differential regulation of EAAT2 expression by NF-kB. (A) TNFa signals to IKK to trigger IkB phosphorylation and
degradation, thereby eliciting NF-kB nuclear translocation, DNA binding and transcriptional repression of EAAT2. We propose that TNFa
functions to induce NF-kB DNA binding as well as regulate different signaling pathways and/or other regulators, such as N-myc, to convert NF-
kB to a transcriptional repressor. (B) EGF signaling regulates the activity of pre-existing NF-kB nuclear complexes to induce transcriptional
activation. EGF may also regulate the activity or recruitment of other regulators at the promoter that cooperate with NF-kB to regulate
positively EAAT2 transcription.
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Materials and methods
Cell culture and reagents
Human H4 astroglioma cells were obtained from ATCC (HTB-148)
and cultured in DMEM (Sigma), 10% fetal bovine serum (FBS;
Sigma) and 1 pen-strep (Invitrogen). H4 cultures were switched
to 0.5% serum for 14–24 h before treating with TNFa or EGF. TNFa
(Promega) was used at a concentration of 20 ng/ml. EGF (Upstate)
was used at 50 ng/ml. All oligos for EMSA, DAPA and PCR analyses
were obtained from Integrated DNA Technologies. H4 cells stably
expressing IkBa-SR were generated as described previously for
MC615 cells (Sitcheran et al, 2003).
Quantitative real-time RT–PCR analysis
Total RNA was prepared from wild-type H4 astroglial cells or H4
cells expressing vector or IkBa-SR according to the manufacturer’s
protocol for RNeasy (Qiagen). cDNA was transcribed with random
primers and MMLV reverse transcriptase. Quantitative real-time
PCR analysis of EAAT2 cDNA was performed using Taqmans
Assays-on-DemandTM for EAAT2 (Applied Biosystems assay #
Hs00188189_m1) in an ABI Prism Sequence Detection System 7000.
Electrophoretic mobility shift assays
EMSAs were performed as previously described (Mayo et al, 2001).
Briefly, 4–5mg of nuclear extracts was prepared following cell
stimulation and incubated with a radiolabeled DNA probe containing
an NF-kB consensus site from the EAAT2 promoter (described below).
For supershifts, 1ml of anti-p65 antibody (Rockland) or 2ml of anti-p50
antibody (Santa Cruz, SC-7178) was added and the binding reaction
was allowed to proceed for an additional 15min. Protein–DNA
complexes were resolved on a nondenaturing polyacrylamide gel and
visualized by autoradiography. The following oligo pairs were
annealed in STE buffer (10mM Tris pH 8, 50 mM NaCl, 1 mM EDTA)
and klenow-labeled with [a-32P]CTP: EkB (583) wild type, 50-
GGCGGAGACGGAGGGGCATCCCGGGTCTCCGCGCGGTC-30 and 50-GA
CCGCGCGGAGACCCGGGATGCC-30; EkB (583) mutant, 50-GGCGGA
GACGGAGGTTCATCAAAGGGTCTCCGCGCGGTC-30 and 50-GACCGCG
CGGAGACCCTTTGATGA-30; EkB (þ 265) wild type, 50-GCTGAAGAG
GAGGGGGCGTTCCCAGACCATGCATC-30 and 50-GATGCATGGTCTGG
GAACGCCCCC; EkB (þ 265) mutant, 50-GCTGAAGAGGAGGGTTCG
TTCAAAGACCATGCATC-30 and 50-GATGCATGGTCTTTGAACGAACCC-
30. NF-kB consensus sequences are underlined and mutated sites are
indicated in bold.
DNA affinity purification assays
DAPA experiments were performed using the mMACS Streptavidin Kit
(Miltenyi Biotec) according to the manufacturer’s specifications.
Briefly, 1mg of 50-biotinylated, duplexed oligo corresponding to the
EkB (583) wild-type site (described above for EMSA) or the N-myc
522 site (GTGACCTGGGGCCACGCGGGCTTCAGGGGA) was
coupled to streptavidin microbeads for 30 min at 41C. N-myc
consensus E-box site is indicated in bold. A 100 ng portion of nuclear
extracts was added and allowed to bind for an additional 30 min.
DNA–protein complexes were immobilized magnetically and washed
four times with 20 mM HEPES–KOH pH 7.9, 100 mM KCl and 2.5 mM
MgCl2. Specifically bound proteins were eluted with 20 mM HEPES–
KOH pH 7.9 and 1 M NaCl. Eluates were run on denaturing
polyacrylamide gels for subsequent Western blot analysis.
Chromatin immunoprecipitation assays
ChIP analysis was performed as previously described (ref) with
some modifications. Briefly, protein–DNA complexes were cross-
linked with formaldehyde (10 min at room temperature) and cells
were harvested. Cells were either snap-frozen in dry ice/EtOH and
stored at 801C or immediately used. DNA was sonicated to lengths
500–1000 bp and a p65 antibody (Rockland) was used for
immunoprecipitation overnight at 41C. Quantitative real-time PCR
was performed and values were expressed as a percent of total input
DNA for each time point. Primers to amplify the EAAT2 583
promoter region were designed using PrimerExpress (ABI): 50-
ATGTCAGCTCTCGACGAAAATAGA-30 (forward) and 50-GGAGG
GATTGCAAGGTTTAGC-30 (reverse). The same primer set was used
for ChIP experiments with N-myc antibody (Santa Cruz, SC-791).
Transfection and reporter assays
H4 cells were cultured in F12-DMEM containing 10% charcoal-
stripped FBS, penicillin and streptomycin. A total of 1104 cells per
well were seeded in 24-well plates and were transfected with 500 ng
total DNA using FuGene (Roche) or DuoFect (Novagen) according
to the manufacturer’s protocol. In all, 100 ng of EAAT2-luciferase
reporter and 50 ng of pRL-SV40 (Renilla reporter control) DNA were
used for transfection. Media containing 0.5% FBS and EGF (50 ng/
ml) or TNFa (20 ng/ml) were added to the wells for next 48–72 h.
Cells were harvested after 24–48 h of treatment. Luciferase assays
were performed using the Dual Luciferase Assay System (Promega).
Activity was measured using Lmax luminometer (Molecular
Devices). All transfections were performed in triplicate.
Mutagenesis
The wild-type EAAT2 promoter from 954 to þ 45 has been previously
described (Su et al, 2003) and was used for further studies and
mutation analysis. To create mutation at the 583 NF-kB-binding
sequence, the sequence 50-GGGGCATCCCGG-30 was changed to 50-
CATCTGGATTCA-30 by PCR-based mutagenesis. To create a triple
mutant, the 583 mutant construct was used as a template and the
prospective NF-kB-binding sites at 272 and 251 were mutated using
an oligo having mutation at both the points. The sequence at 272 site
50-GGGATCGCCTGCAAATCCCC-30 was changed to 50-GATACTACTAGA-
TAGTACTA-30 and the sequence at 245 site 50-GGGGCTAAACC-30 was
changed to 50-TGGTCTAAACC-30. To generate the mutations in the N-
myc consensus sites, we used the Transformer site-directed mutagen-
esis kit (Clontech) according to the manufacturer’s protocol using the
following oligos: 522 site (50-GTGACCTGGGGCCCCGGGGGCTT
CAGGGG-30) and 163 site (50-CACACACCCGCACCCGGGCACG
CACGTC-30). Mutated residues are indicated in bold. In both cases,
the wild-type CACGCG site was changed to CCCGGG, creating a SmaI
site, which was used to analyze mutant clones. The following oligo was
used to mutate the NheI site in the vector to select for mutagenic events:
50-GCTCTTACGCGTGGCAGCCCGGGCTCGAGATC-30). All reporters
were sequenced to confirm mutations.
Western blot analysis
A 10–20mg portion of protein from whole cell, nuclear or
cytoplasmic lysates was run on precast NuPage gels, blotted onto
nitrocellulose and blocked in TBSTþ 5% nonfat dry milk and 1%
BSA. The following antibodies were used: p65 (Rockland), p50
(Santa Cruz, SC-7178), IkBa (SC-1643), IkBb (SC-8014), IkBg (SC-
8330), b-tubulin (SC-9104), phospho-IkBa (Cell Signaling Technol-
ogy #9246L) and phospho-MEK1/2 (Cell Signaling #9120).
Supplementary data
Supplementary data are available at The EMBO Journal Online.
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